查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561658

2024-2032 年按类型（血友病A、血友病B、血友病C 等）、治疗（按需、预防）、治疗（替代治疗、ITI 治疗、基因治疗）和区域分類的血友病市场报告

Hemophilia Market Report by Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), Treatment (On-Demand, Prophylaxis), Therapy (Replacement Therapy, ITI Therapy, Gene Therapy), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

2023 年，全球血友病市场IMARC Group达到 130 亿美元。

血友病是一种影响血液凝固过程的遗传性医学疾病，其中血液凝固异常。它会导致受伤、手术和牙科手术后自发性出血和过度出血、容易瘀伤和渗血。它是由遗传性缺乏凝血因子引起的，由于缺乏足够的凝血蛋白，凝血因子会减慢血液凝固。可以使用药物、替代疗法和注射凝血因子或血浆来治疗。其治疗重点是替换缺失的蛋白质和预防併发症。

血友病市场趋势：

全球血友病患者数量的增加和个体遗传异常发生率的增加是积极影响市场的关键因素之一。此外，疾病诊断率的上升以及血友病预防性治疗的日益普及，为领先的市场参与者提供了利润丰厚的成长机会。除此之外，各国管理机构正在组织大量活动，以宣传早期诊断的好处，并遵循适当的程序来促进新生儿的早期筛检，这为市场创造了积极的前景。此外，由于治疗方案的可用性有限，他们越来越多地资助研究和开发 (R&D) 活动。此外，领先的产业参与者正致力于引进技术先进的诊断工具和疗法，以提高血友病治疗的功效和准确性，这提供了良好的市场前景。此外，预计在全球范围内扩大建立专门的血友病治疗中心（HTC）的大量投资将推动市场的发展。

本报告回答的关键问题

  • 2023 年全球血友病市场规模有多大？ 2024-2032年全球血友病市场的预期成长率是多少？
  • 推动全球血友病市场的关键因素是什么？
  • COVID-19 对全球血友病市场有何影响？
  • 全球血友病市场按类型划分是怎样的？
  • 根据治疗方法，全球血友病市场的细分如何？
  • 基于该疗法的全球血友病市场的细分情况如何？
  • 全球血友病市场的重点区域有哪些？
  • 全球血友病市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球血友病市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 甲型血友病
    • 市场趋势
    • 市场预测
  • 乙型血友病
    • 市场趋势
    • 市场预测
  • 丙型血友病
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按处理方式

  • 一经请求
    • 市场趋势
    • 市场预测
  • 预防
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：透过疗法

  • 替代疗法
    • 市场趋势
    • 市场预测
  • ITI疗法
    • 市场趋势
    • 市场预测
  • 基因治疗
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Baxter International Inc.
    • Bayer AG
    • BioMarin Pharmaceutical Inc.
    • CSL Behring (CSL Limited)
    • F. Hoffmann-La Roche AG
    • Grifols SA
    • Kedrion SpA
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112024A4508

The global hemophilia market size reached US$ 13.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 31.2 Billion by 2032, exhibiting a growth rate (CAGR) of 9.9% during 2024-2032.

Hemophilia is an inherited medical disorder that affects the blood clotting process, wherein the blood clots abnormally. It results in spontaneous and excessive bleeding, easy bruising, and oozing after an injury, surgery, and dental procedures. It is caused by a hereditary lack of a coagulation factor that slows down blood clotting due to the deficiency of adequate blood-clotting proteins. It can be treated using medications, replacement therapy and injections of a clotting factor or plasma. Its treatment focuses on replacing missing proteins and preventing complications.

Hemophilia Market Trends:

The increasing number of hemophilic patients and rising occurrences of genetic abnormalities among individuals across the globe represents one of the key factors positively influencing the market. In addition, the rising diagnosis rate of the illness and the growing popularity of prophylactic treatment to cure hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, governing agencies of various countries are organizing numerous campaigns to spread awareness about the benefits of early diagnosis and following appropriate procedures to facilitate the early screening of neonates, which is creating a positive outlook for the market. Additionally, they are increasingly funding research and development (R&D) activities due to the limited availability of treatment options. Furthermore, leading industry players are focusing on introducing technologically advanced diagnostic tools and therapies to enhance the efficacy and accuracy of hemophilia treatment, which is offering a favorable market outlook. Moreover, extensive investments in expanding the establishment of specialized hemophilia treatment centers (HTCs) across the globe are anticipated to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, treatment, and therapy.

Breakup by Type:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Hemophilia A represents the largest market segment due to the rising prevalence of hemophilia A among individuals across the globe and the increasing requirement for patient care.

Breakup by Treatment:

  • On-Demand
  • Prophylaxis

On-demand treatment currently holds the largest market share as it is highly beneficial for patients with mild or moderate hemophilia who bleed less often.

Breakup by Therapy:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy

Replacement therapy is a standard therapy used to treat hemophilia as it helps replace the missing clotting factor among patients. It involves offering the missing clotting factor to patients from an external source.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market due to the increasing government spending on healthcare and research and development (R&D) activities, along with the presence of various leading players in the country.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report

  • 1. What was the size of the global hemophilia market in 2023?
  • 2. What is the expected growth rate of the global hemophilia market during 2024-2032?
  • 3. What are the key factors driving the global hemophilia market?
  • 4. What has been the impact of COVID-19 on the global hemophilia market?
  • 5. What is the breakup of the global hemophilia market based on the type?
  • 6. What is the breakup of the global hemophilia market based on the treatment?
  • 7. What is the breakup of the global hemophilia market based on the therapy?
  • 8. What are the key regions in the global hemophilia market?
  • 9. Who are the key players/companies in the global hemophilia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemophilia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hemophilia B
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hemophilia C
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 On-Demand
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Prophylaxis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Therapy

  • 8.1 Replacement Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 ITI Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Gene Therapy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Baxter International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 BioMarin Pharmaceutical Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 CSL Behring (CSL Limited)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Grifols S.A.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Kedrion S.p.A.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Octapharma AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemophilia Market: Major Drivers and Challenges
  • Figure 2: Global: Hemophilia Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hemophilia Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hemophilia Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Hemophilia Market: Breakup by Treatment (in %), 2023
  • Figure 6: Global: Hemophilia Market: Breakup by Therapy (in %), 2023
  • Figure 7: Global: Hemophilia Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Hemophilia (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Hemophilia (On-Demand) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Hemophilia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Hemophilia Industry: SWOT Analysis
  • Figure 76: Global: Hemophilia Industry: Value Chain Analysis
  • Figure 77: Global: Hemophilia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemophilia Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million US$), 2024-2032
  • Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Hemophilia Market: Competitive Structure
  • Table 7: Global: Hemophilia Market: Key Players